Prs59 Qualitative Assessment of the Content Validity of the Snot-22 in Patients With Nasal Polyps

Abstract

Objectives: Asthma affects more than 300 million people worldwide and over 26 million people in the US. Incidence of psychological distress (PD) in asthma, a consequence of coexisting psychological comorbidities like anxiety and/or depression, is on the rise. The study aims to identify sociodemographic and other factors that are associated with PD and assess its impact specifically on reliever medication use in Asthma. Methods: A retrospective, cross-sectional research data, obtained from the Medical Expenditure Panel Survey (MEPS, 2013(MEPS, -2015 and consisted of a sample of 5307 community dwelling asthmatics. PD was identified by using Kessler-6 scale (a score of $ 13), a self-administered written questionnaire embedded in MEPS. Use of three or more canisters of quick relief inhalers was defined as overuse of relievers. A Chi-square analyses was performed to test association between PD and reliever use. A set of logistic regression (LR) analyses was performed to determine the predictors of PD as well as reliever overuse in asthmatics with PD. Results: Compared to those without distress, a higher proportion of psychologically distressed asthmatics reported reliever overuse (2=310956.703, 23.3% vs 12.2%, p,0.0001). Female asthmatics were 32.3% more likely to have PD than males (OR=1.323, C.I=1.320-1.326, p,0.0001). The LR results revealed that female asthmatics within the PD group were more likely to overuse relievers than males (OR= 2.263, C.I= 2.255-2.2343, p,0.0001), and those with 12 years or more of education were less likely to overuse relievers compared to those with less education (OR=0.555, C.I=0.553-0.556, p,0.0001). A Phi correlation coefficient (r4=-0.103) revealed a significant negative correlation between PD scores and reliever overuse. Conclusions: Comorbidity of PD in asthma is associated with over-utilization of reliever medications. Inappropriate medication use can affect treatment plan, compromise patient's quality of life, and increase the overall cost of care in asthma.

Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study

“…Since CRSwNP significantly impacts health-related quality of life (HRQoL) [ 12 , 15 , 16 ], clinical trials assessing the efficacy of novel treatments in patients with CRSwNP have included patient-reported outcome measures (PROMs) to evaluate symptom severity (HRQoL via the use of, for example, the visual analogue scale (VAS) and Sino-nasal Outcome Test (SNOT)-22, respectively, as supported by the European Position Paper on Rhinosinusitis and Nasal Polyposis (EPOS 2020) [ 1 ]. The psychometric properties of the VAS were assessed in a Phase II study assessing mepolizumab clinical efficacy in CRSwNP [ 17 ]. The analyses indicated that although overall patient comprehension of the VAS was good, there was room for improvement.…”